Skip to content
DataLookout
Menu

Alnylam Pharmaceuticals clinical trial pipeline

Get alerts when Alnylam Pharmaceuticals's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

7 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 7 with minor changes only.

  1. Minor: Mivelsiran · Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) Trial sites expanded: 10 → 20 locations Alnylam PharmaceuticalsPhase 2 NCT07636811
  2. Minor: TRITON-CM · Nucresiran · Transthyretin Amyloidosis With Cardiomyopathy Enrollment increased: 1750 → 2250 participants Alnylam PharmaceuticalsPhase 3 NCT07052903
  3. Minor: ALN-4324 on Insulin Sensitivity · Type 2 Diabetes Mellitus Enrollment closed, study ongoing Alnylam PharmaceuticalsPhase 2 NCT07465224
  4. Minor: HMBeacon · ALN-6400 in Adult and Adolescent Female · VWD and HMB Trial sites expanded: 21 → 29 locations Alnylam PharmaceuticalsPhase 2 NCT07575308
  5. Minor: ZENITH · Zilebesiran · Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease Trial sites expanded: 1190 → 1226 locations Alnylam PharmaceuticalsPhase 3 NCT07181109
  6. Minor: HELIOS-B · Vutrisiran · Transthyretin Amyloidosis With Cardiomyopathy Study completion pushed from Dec 2, 2026 to Jan 13, 2027 Alnylam PharmaceuticalsPhase 3 NCT04153149
  7. Minor: ALN-APP · EOAD Primary and study completion moved earlier from Apr 20, 2029 to Jan 11, 2029 Alnylam PharmaceuticalsPhase 1 NCT05231785
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Active trials by phase

Phase 1
7
Phase 1/2
3
Phase 2
5
Phase 3
5
Not charted: 6 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials

Get alerts when Alnylam Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free